Cancer Institute A national cancer institute
designated cancer center

Philip W. Lavori

Publication Details

  • EFFECT OF SULINDAC ON SPORADIC COLONIC POLYPS GASTROENTEROLOGY LADENHEIM, J., Garcia, G., Titzer, D., HERZENBERG, H., Lavori, P., Edson, R., Omary, M. B. 1995; 108 (4): 1083-1087


    We sought to determine in a double-blinded, placebo-controlled study if the nonsteroidal anti-inflammatory drug sulindac causes regression of sporadic colonic polyps. The impetus for this study is the profound regressive effect of sulindac on polyps in familial adenomatous polyposis.Asymptomatic patients undergoing routine screening flexible sigmoidoscopy were enrolled if they had polyps of < or = 1 cm in size. Of 162 patients screened, 22 patients were randomly enrolled to take 150 mg of sulindac twice daily, and 22 patients took a placebo. Treatment duration was 4 months and was followed by colonoscopy with removal of all polyps.Four patients were dropped from the study (sulindac group) due to urosepsis (1 patient), heartburn (2 patients), and anemia (1 patient). Compliance (determined by monthly pill counting), mean age, and the effect of sulindac vs. placebo on polyp regression or size were not statistically different in the two treatment groups. Analysis of our data indicated that there is only a 0.8% chance that the probability of polyp regression with sulindac is as large as 50%.Four months of treatment with sulindac does not result in a clinically significant regression of sporadic colonic polyps, although a small effect may not have been detected by the size of our study. Our data suggest that the biological response of sporadic and familial polyposis polyps to sulindac is different.

    View details for Web of Science ID A1995QP79200017

    View details for PubMedID 7698575

Stanford Medicine Resources:

Footer Links: